



Revista Portuguesa de
Cardiologia
Portuguese Journal of **Cardiology**
www.revportcardiol.org



Índice numérico

Comunicações orais

- CO 1 UNDERSTANDING THE UNDERPINNING OF HYPERTRIGLYCERIDEMIA AS A RISK FACTOR FOR ATHEROSCLEROSIS
- CO 2 THE ROLE OF AGE ON LIPID-LOWERING THERAPY PRESCRIPTIONS AND ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) CONTROL: A SUBANALYSIS OF THE PORTRAIT-DYS STUDY
- CO 3 THE ROLE OF THE PHACTR1 GENE IN CORONARY ARTERIAL DISEASE IN SMOKERS WITH FEW OTHER CARDIOVASCULAR RISK FACTORS.
- CO 4 FIBRINOGEN IS CORRELATED TO INCREASED ARTERIAL STIFFNESS ON HYPERTENSIVE INDIVIDUALS
- CO 5 INVESTIGATING THE EFFECTS OF 5 α -ESTRADIOL ON HUMAN MICROVASCULAR ENDOTHELIAL CELLS: A FOCUS ON SEX DIFFERENCES IN CARDIAC HEALTH
- CO 6 PULMONARY ARTERY PULSE PRESSURE AS A PREDICTOR OF PULMONARY HYPERTENSION IN PATIENTS WITH INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM
- CO 7 IMPROVING RISK PREDICTION IN PULMONARY HYPERTENSION: THE ROLE OF PULMONARY ARTERIAL COMPLIANCE
- CO 8 PERSUING VENTRICULAR-ARTERIAL COUPLING: PROPOSING A NEW CUT-OFF OF TAPSE/SPAP TO IDENTIFY PATIENTS WITH PULMONARY HYPERTENSION AFTER INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM
- CO 9 PULMONARY ENDARTERECTOMY AND BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: COMPARISON OF LONG-TERM HEMODYNAMIC RESPONSES TO EXERCISE
- CO 10 TAPSE/PASP RATIO: UNVEILING A KEY PREDICTOR OF PULMONARY HYPERTENSION IN ACUTE PULMONARY EMBOLISM
- CO 11 MAPPING HEART FAILURE CARE IN PORTUGAL: ACCESS, RESOURCES, AND REGIONAL INEQUITIES
- CO 12 SOCIOECONOMIC AND ETHNIC FACTORS AFFECTING HEART FAILURE TREATMENT AND PROGNOSIS: EXPLORING DISPARITIES IN CLINICAL OUTCOMES
- CO 13 THE EXPERIENCE OF 253 EARLY POST DISCHARGE HEART FAILURE APPOINTMENTS: WHAT WE HAVE LEARNED
- CO 14 TRENDS IN CARDIOVASCULAR HOSPITAL ADMISSIONS OVER THE LAST 15 YEARS: IS IT TIME TO RETHINK HEALTHCARE POLICIES?
- CO 15 MORTALITY AND HOSPITALIZATION COSTS DUE TO HEART FAILURE ASSOCIATED WITH SYSTEMIC ARTERIAL HYPERTENSION IN BRAZIL FROM 2010 TO 2019
- CO 16 OUTCOMES AND PROCEDURAL BURDEN OF CULPRIT-ONLY VS. MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION IN CARDIOGENIC SHOCK: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
- CO 17 FULMINANT ACUTE MYOCARDITIS IN THE CARDIAC INTENSIVE CARE UNIT - A LONG BUT SUCCESSFUL ROAD TO RECOVERY
- CO 18 IMPACT OF DANGER SHOCK ELIGIBILITY CRITERIA ON SURVIVAL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION-RELATED CARDIOGENIC SHOCK: IT IS ALL ABOUT IMPELLA?
- CO 19 EXPLORING THE SAFETY AND EFFICACY OF RENAL DENERVATION IN ELECTRICAL STORM MANAGEMENT
- CO 20 CHANGING THE PARADIGM IN ACUTE CORONARY SYNDROMES: FROM STEMI VS. NSTEMI TO OMI VS. NON-OMI
- CO 21 LEFT BUNDLE BRANCH PACING AND MECHANICAL DESYNCHRONY: A REAL-WORLD PERSPECTIVE
- CO 22 LEFT BUNDLE BRANCH AREA PACING: LONGITUDINAL DATA ON PACING EFFICACY
- CO 23 ADOPTION OF AN ECHO-GUIDED AXILLARY PUNCTURE WORKFLOW IS ASSOCIATED WITH FASTER PROCEDURAL DURATION IN TRANSVENOUS PACEMAKER IMPLANTATION

- CO 24 PREDICTORS AND PROGNOSIS OF LEAD RELATED TRICUSPID REGURGITATION
- CO 25 VENTRICULAR PACING RATE AND VENTRICULAR PACING DEPENDENCY IN PATIENTS REQUIRING PERMANENT PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 26 DIFFERENTIATING TRANSTHYRETIN CARDIAC AMYLOIDOSIS AMONG LEFT VENTRICULAR HYPERTROPHY PHENOTYPES: THE ROLE OF RIGHT AND LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN
- CO 27 ECHOCARDIOGRAPHIC PREDICTORS OF DEATH IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- CO 28 PREDICTORS OF ATRIAL FIBRILLATION IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- CO 29 DECODING THE DECADES: TAFAMIDIS EFFICACY ACROSS DIFFERENT AGE GROUPS IN ATTR-CM PATIENTS
- CO 30 AMYLOID CARDIOMYOPATHY: SPECIFICITIES OF TRANSTHYRETIN V30 MUTATION COMPARED TO WILD TYPE FORMS
- CO 31 IMPACT OF LIPOPROTEIN A ON LONG-TERM OUTCOMES IN ACUTE CORONARY SYNDROME: A RETROSPECTIVE COHORT ANALYSIS
- CO 32 CORONARY ARTERY DISEASE AND THE BAD DUAL: HOMOCYSTEINE AND LIPOPROTEIN (A)
- CO 33 ASSOCIATIONS BETWEEN AN INSULIN RESISTANCE INDEX AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION IN A CORONARY POPULATION
- CO 34 C-REACTIVE PROTEIN LEVEL AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE
- CO 35 IDENTIFYING REDUCE-IT TRIAL ELIGIBLE PATIENTS IN A STRUCTURED CORONARY DISEASE FOLLOW-UP PROGRAM
- CO 36 FINDING THE PERFECT MATCH: PROFILING AORTIC ANNULUS IN TAVI PATIENTS
- CO 37 TRANSCATHETER AORTIC VALVE IMPLANTATION WITHOUT CARDIAC SURGERY BACKUP: FIRST NATIONAL SINGLE-CENTER EXPERIENCE ASSESSING SAFETY AND EFFICACY OUTCOMES
- CO 38 EXPLORING IMPLANTATION DEPTH AND PROCEDURAL OUTCOMES IN TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 39 TAVI PARAVALVULAR LEAKS - 1 YEAR EVALUATION AND MULTIMODAL PREDICTORS
- CO 40 IS SMART ENOUGH? BEV VS SEV IN PATIENTS WITH SMALL AORTIC ANNULI
- CO 41 UNFREEZING THE PATH WITH ICE-ING: REVOLUTIONIZING LEFT ATRIAL APPENDAGE OCCLUSION
- CO 42 IMPROVING PATIENT SELECTION FOR PERCUTANEOUS SUTURE-MEDIATED PATENT FORAMEN OVALE CLOSURE: THE SWAT CRITERIA
- CO 43 PERCUTANEOUS SUTURE-MEDIATED PATENT FORAMEN OVALE CLOSURE: RESULTS FROM THE LARGEST NATIONAL REGISTRY
- CO 44 TRANSCATHETER PULMONARY VALVE IMPLANTATION EXPERIENCE IN A PORTUGUESE CONGENITAL HEART DISEASE CENTER
- CO 45 TO STENT OR NOT TO STENT IN TRUE BIFURCATION: WHAT IS THE BEST APPROACH FOR THE SIDE BRANCH IN A LEFT MAIN ARTERY BIFURCATION?
- CO 46 CLINICAL OUTCOMES OF TAVI IN PATIENTS WITH ACTIVE CANCER - A BRIDGE TO SUCCESS?
- CO 47 CLOSING THE GAP: LEFT ATRIAL APPENDAGE OCCLUSION IN ATRIAL FIBRILLATION PATIENTS WITH CANCER
- CO 48 BODY FAT AS A PREDICTOR OF IMPAIRED CARDIORESPIRATORY FITNESS IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES
- CO 49 META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON THE EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN LEFT VENTRICULAR THROMBOSIS: AN UPDATED PERSPECTIVE
- CO 50 INAPPROPRIATE DIRECT ORAL ANTICOAGULANT DOSING IN ATRIAL FIBRILLATION: A PORTUGUESE SINGLE-CENTER STUDY
- CO 51 INTERMITTENT LEVOSIMENDAN AND SURVIVAL OUTCOMES IN ADVANCED HEART FAILURE: A REAL-WORLD, SINGLE-CENTRE STUDY
- CO 52 IMPACT OF FUNCTIONAL MITRAL REGURGITATION ON OUTCOMES FOLLOWING CARDIAC RESYNCHRONIZATION THERAPY FOR HEART FAILURE
- CO 53 CRT-P VS CRT-D IN NON-ISCHEMIC CARDIOMYOPATHY: STILL A MATTER OF DEBATE
- CO 54 THE RELATIONSHIP BETWEEN SEX AND CARDIAC RESYNCHRONIZATION THERAPY: WHAT ABOUT WOMEN?
- CO 55 REDUCING THE BURDEN OF ADVANCED HEART FAILURE: A CLINICAL AND ECONOMICAL ANALYSIS OF AN INTERMITTENT LEVOSIMENDAN PROGRAMME
- CO 56 ZERO-FLUOROSCOPY ATRIAL FIBRILLATION ABLATION: INITIAL EXPERIENCE IN A SINGLE-CENTER COHORT
- CO 57 PULSED FIELD ABLATION: A NEW STANDARD FOR SINGLE-SHOT ATRIAL FIBRILLATION ABLATION

- CO 58 ELECTROPHYSIOLOGICAL CHARACTERIZATION OF TACHYCARDIA CIRCUIT AND UNDERLYING SUBSTRATE IN ATYPICAL ATRIAL FLUTTERS
- CO 59 VALIDATION OF IMAGELESS ELECTROCARDIOGRAPHIC IMAGING FOR ACCESSORY PATHWAY LOCALISATION IN WPW SYNDROME
- CO 60 LONG-TERM OUTCOMES OF VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS PRESENTING WITH ELECTRICAL STORM
- CO 61 DIAGNÓSTICO DE DOENÇA CORONÁRIA ESTÁVEL POR ANGIO TOMOGRAFIA COMPUTADORIZADA COMO EXAME DE PRIMEIRA LINHA: ANÁLISE DE CUSTOS NUM CENTRO DE RESPONSABILIDADE INTEGRADA
- CO 62 ASSESSMENT OF MYOCARDIAL BLOOD FLOW CHANGES USING $[^{13}\text{N}]\text{NH}_3$ PET-CT IN CHRONIC TOTAL CORONARY OCCLUSION PATIENTS UNDERGOING PCI
- CO 63 ASSOCIATION BETWEEN ABDOMINAL FAT DISTRIBUTION AND SEVERITY OF CORONARY ARTERY DISEASE: DATA FROM A LARGE COHORT OF PATIENTS SUBMITTED TO CARDIAC CT SCAN
- CO 64 STRUCTURAL INVASIVELY-ASSESSED CORONARY MICROVASCULAR DYSFUNCTION PHENOTYPE ASSOCIATES WITH THE PRESENCE OF MYOCARDIAL FIBROSIS IN CARDIAC MAGNETIC RESONANCE
- CO 65 EPICARDIAL ADIPOSE TISSUE VOLUME ARE RELATED TO SUBCLINICAL ATHEROSCLEROSIS AND MAJOR ADVERSE CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS
- CO 66 ECGI TO GUIDE VT ABLATION IN STRUCTURAL HEART DISEASE
- CO 67 SUBCLINICAL FOCAL FIBROSIS AND ABNORMAL LEFT VENTRICULAR STRAIN IN PATIENTS WITH SARCOIDOSIS WITHOUT CLINICAL EVIDENCE OF CARDIAC DISEASE
- CO 68 CAN MY ECHO WORK AS A CRYSTALBALL? - ECHOCARDIOGRAPHIC PARAMETERS PREDICTING RESIDUAL PULMONARY HYPERTENSION AFTER PULMONARY ENDARTERECTOMY
- CO 69 MYOCARDIAL WORK AND EXERCISE LVEF AS PREDICTORS OF IMPAIRED CARDIORESPIRATORY FITNESS IN BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES
- CO 70 INCREMENTAL PROGNOSTIC VALUE OF CT-DERIVED EXTRACELLULAR VOLUME IN SEVERE AORTIC STENOSIS
- CO 71 COULD CHATGPT BE A CARDIOLOGY RESIDENT IN PORTUGAL?
- CO 72 PRELIMINARY RESULTS FROM THE EXTERNAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE MODEL FOR OCCLUSION MYOCARDIAL INFARCTION DETECTION
- CO 73 PHENOTYPING HEART FAILURE WITH REDUCED EJECTION FRACTION: A MACHINE LEARNING APPROACH TO PATIENT STRATIFICATION
- CO 74 IMPROVING PACEMAKER IMPLANTATION PREDICTION AFTER TAVR: CREATION AND VALIDATION OF A MACHINE LEARNING BASED MODEL
- CO 75 ACUTE KIDNEY INJURY POST-TAVI: DOES IT STILL IMPACT PROGNOSIS?
- CO 76 MAVACAMTEN USE IN A REAL-WORLD COHORT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS: INSIGHTS FROM THE INITIAL CENTRE EXPERIENCE
- CO 77 EFFECT OF MAVACAMTEN ON THE REMODELLING AND MICROSTRUCTURAL ARCHITECTURE OF THE MYOCARDIUM: A PRELIMINARY MECHANISTIC STUDY
- CO 78 ECHOCARDIOGRAPHIC EVOLUTION OF SYMPTOMATIC PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TREATED WITH MAVACAMTEN: EXPERIENCE OF A PORTUGUESE TERTIARY CARE CENTER
- CO 79 THE INFLUENCE OF GENOTYPE ON THE PHENOTYPE AND PROGNOSIS OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY:
- CO 80 "RING-LIKE" LATE GADOLINIUM ENHANCEMENT: EXPLORING PATTERNS AND OUTCOMES
- CO 81 MYERS AND MECKI SCORES IN CARDIAC REHABILITATION - COMPREHENSIVE AND SIMPLE AND RELIABLE TOOLS FOR RISK STRATIFICATION.
- CO 82 THE ROLE OF PEAK VO₂ IN CARDIAC REHABILITATION: PREDICTORS OF NON-RESPONSE AND THEIR IMPACT ON LONG-TERM OUTCOMES
- CO 83 NONSPECIFIC VENTRICULAR REPOLARIZATION ABNORMALITIES: A BENIGN FINDING OR A PROGNOSTIC CONCERN?
- CO 84 REALLY WORTH THE EFFORT: UNVEILING EXERCISE PULMONARY HYPERTENSION - A SINGLE CENTRE EXPERIENCE
- CO 85 TEACHING YOUR HEART TO HEAL: THE ROLE OF PATIENT EDUCATION IN IMPROVING OUTCOMES IN PRIMARY ANGIOPLASTY FOR STEMI
- CO 86 PROGNOSTIC VALUE OF STRESS PERFUSION CARDIAC MAGNETIC RESONANCE: REAL-WORLD EVIDENCE FROM A LARGE PORTUGUESE COHORT
- CO 87 REDUCED MRI-BASED RIGHT-TO-LEFT VENTRICULAR BLOOD POOL T2 RATIO PREDICTS ADVERSE EVENTS AND IMPAIRED CARDIOPULMONARY FUNCTION IN HEART FAILURE PATIENTS

- CO 88 EPICARDIAL ADIPOSE TISSUE PLAYS AN ADDITIONAL ROLE IN CARDIOVASCULAR RISK ASSESSMENT TOGETHER WITH CORONARY ARTERY CALCIUM SCORE
- CO 89 INCREMENTAL PROGNOSTIC ROLE OF LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN AFTER ACUTE MYOCARDIAL INFARCTION
- CO 90 CHARACTERISATION OF LEFT ATRIAL DEFORMATION DURING CARDIOVASCULAR REVERSE REMODELLING INDUCED BY PREGNANCY AND ITS POTENTIAL PREDICTORS
- CO 91 EFFECTIVE REGURGITANT ORIFICE AREA AND LEFT VENTRICULAR VOLUME IMPACT ON HOSPITALIZATIONS EFFECTS OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-REGRESSION ANALYSIS
- CO 92 PROGNOSTIC IMPACT OF MITRAL BALLOON VALVULOPLASTY FOR MITRAL STENOSIS PATIENTS: WHEN THE RIGHT HEART CATHETERIZATION IS THE ANSWER
- CO 93 THE IMPACT OF AORTIC DISTENSIBILITY IN PATIENTS WITH BICUSPID AORTIC VALVE STENOSIS
- CO 94 CALCIUM IDENTIFICATION AND SCORING BASED ON 3D TRANSESOPHAGEAL ECHOCARDIOGRAPHY - AN EXPLORATORY STUDY ON AORTIC VALVE STENOSIS
- CO 95 AGING HEARTS: TRANSCATHETER AORTIC VALVE REPLACEMENT ASSESSMENT IN THE NONAGENARIAN POPULATION - A SINGLE CENTER EXPERIENCE
- CO 96 IMPACT OF USING THE 2024 ESC GUIDELINE-RECOMMENDED METHOD FOR ESTIMATING THE LIKELIHOOD OF OBSTRUCTIVE CORONARY DISEASE - A CARDIAC CT STUDY
- CO 97 STENT PERFORMANCE IN THE SPOTLIGHT: SIMULATION USING 3D-PRINTED BIFURCATION MODELS
- CO 98 MACHINE LEARNING ALGORITHMS FOR PREDICTING ARRHYTHMIC EVENTS IN HYPERTROPHIC CARDIOMYOPATHY: LIMITED ENHANCEMENT BEYOND LATE GADOLINIUM ENHANCEMENT
- CO 99 DYNAMIC CT PERFUSION TO IDENTIFY HEMODYNAMICALLY SIGNIFICANT CORONARY ARTERY DISEASE: PRELIMINARY RESULTS OF A "ONE-STOP-SHOP" APPROACH
- CO 100 RADIOMICS-BASED ARTIFICIAL INTELLIGENCE MODEL ALLOWS FOR PERSONALIZED PREDICTION OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- CO 101 LESS-INVASIVE AORTIC VALVE REPLACEMENT: MID-TERM SINGLE-CENTER RESULTS
- CO 102 DEVELOPMENT AND VALIDATION OF AN OPEN-SOURCE 3D SLICER PLUGIN FOR TAVI SIZING

Posters

- PO 1 THE ROLE OF PHASE 3 CARDIAC REHABILITATION IN BOOSTING PEAK VO2 AND PREDICTING CLINICAL SUCCESS
- PO 2 IMPROVEMENT IN CARDIOPULMONARY EXERCISE TEST PARAMETERS PHASE 2 REHABILITATION AND ITS IMPACT ON CLINICAL OUTCOMES
- PO 3 THE CLINICAL AND HOLISTIC IMPACT OF A PROGRAM OF CARDIAC REHABILITATION
- PO 4 IMPACT OF COMPLETING CARDIAC REHABILITATION PROGRAM ON CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME
- PO 5 UNLOCKING PHYSICAL POTENTIAL: THE CRUCIAL ROLE OF CARDIAC REHABILITATION IN ENHANCING PHYSICAL CAPACITY
- PO 6 AWARENESS OF COMPETITIVE ATHLETES REGARDING CARDIOVASCULAR PROFILE, SPORTS MEDICINE EVALUATION AND EMERGENCY SUPPORT - SUPPORT STUDY
- PO 7 SECONDARY PREVENTION AFTER ONE-YEAR OF A CARDIOVASCULAR REHABILITATION PROGRAM - A SINGLE-CENTRE ANALYSIS
- PO 8 CLINICAL CHALLENGES IN CARDIOVASCULAR REHABILITATION PROGRAMS: PREDICTORS OF DROPOUT - A SINGLE-CENTRE ANALYSIS
- PO 9 AGE-RELATED DIFFERENCES IN CARDIOVASCULAR REHABILITATION PROGRAMS - A SINGLE-CENTRE ANALYSIS
- PO 10 EXPLORING PEAK CIRCULATORY POWER AND ITS CORRELATION WITH EXERCISE TEST PARAMETERS IN CARDIAC REHABILITATION
- PO 11 LONG-TERM IMPACT OF EXERCISE-BASED CARDIAC REHABILITATION ON CARDIORESPIRATORY FITNESS AND PHYSICAL FUNCTION
- PO 12 IMPACT OF STRUCTURED CARDIAC REHABILITATION ON PATIENT OUTCOMES: A PROSPECTIVE COHORT ANALYSIS
- PO 13 BODY MASS INDEX AS A PREDICTOR OF CLINICAL AND FUNCTIONAL OUTCOMES IN CARDIAC REHABILITATION
- PO 14 INFLUENCE OF CARDIAC REHABILITATION ADHERENCE ON CARDIOVASCULAR OUTCOMES

- PO 15 PHASE 2 CARDIOVASCULAR REHABILITATION: A STUDY ON POPULATION PROFILES AND OUTCOMES
- PO 16 ADHERENCE TO PHASE 3 CARDIAC REHABILITATION: PREDICTORS AND OUTCOMES
- PO 17 ROLE OF PHASE 3 CARDIAC REHABILITATION IN IMPROVING CARDIORESPIRATORY FITNESS
- PO 18 CARDIAC REHABILITATION PHASE 3 - WHO ARE THEY?
- PO 19 ASSOCIATION OF AN ATTR CARDIOMYOPATHY RISK SCORE WITH CARDIAC AND KIDNEY OUTCOMES AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE - INSIGHTS FROM CRIC
- PO 20 FUNCTIONAL CAPACITY ASSESSMENT FOR TAFAMIDIS TREATMENT IN CARDIAC AMYLOIDOSIS PATIENTS
- PO 21 TEVAR PLUS BALLOON EXPANDABLE STENT: A NOVEL HYBRID ENDOVASCULAR APPROACH FOR COMPLEX COARCTATION OF AORTA REPAIR.
- PO 22 CHARACTERISATION OF PRE-INTERVENTION OUTCOMES IN VERY OLD PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 23 AORTIC VALVE REPLACEMENT IN OCTOGENARIANS: IMPACT ON AGE-EXPECTED SURVIVAL
- PO 24 TRANSFORMING MULTIMODAL STETHOSCOPE SIGNAL QUALITY: THE ROLE OF OPERATOR TRAINING AND FEEDBACK IN ECG AND PCG CLARITY
- PO 25 OUTCOMES WITH PLUG-BASED VERSUS SUTURE-BASED VASCULAR CLOSURE DEVICE AFTER TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
- PO 26 VASCULAR COMPLICATIONS AFTER MANTA VASCULAR CLOSURE DEVICE FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 27 EARLY DISCHARGE SAFETY IN TAVI PATIENTS WITH NEW-ONSET LEFT BUNDLE BRANCH BLOCK
- PO 28 OPTIMIZING TAVI - SHOULD PREEMPTIVE PACING BE CONSIDERED IN ADVANCED CONDUCTION DISEASE?
- PO 29 INITIAL EXPERIENCE WITH EVOLUT FX: HOW DOES IT MEASURE UP?
- PO 30 PROGNOSTIC VALUE OF QRS VARIATION FOLLOWING TAVI: A PREDICTOR OF LEFT VENTRICULAR DYSFUNCTION AND MORTALITY AT 1-YEAR FOLLOW UP
- PO 31 CLINICAL PROFILING ON CLUSTERING TAVI PATIENTS: MULTIVARIATE ANALYSIS OF RISK FACTORS, CLINICAL PRESENTATION, AND OUTCOME ASSOCIATION
- PO 32 A COMPARISON OF SELF-EXPANDING AND BALLOON-EXPANDABLE VALVES IN PACEMAKER IMPLANTATION RATES IN TAVI
- PO 33 COMPARATIVE ANALYSIS OF DEVICE PERFORMANCE AND PACEMAKER IMPLANTATION RATES IN SUPRA-ANULAR AND INTRA-ANULAR TAVR VALVES IN PATIENTS WITH SMALL AORTIC ANNULI
- PO 34 A COMPREHENSIVE CHARACTERIZATION OF FAMILIAL AMYLOID POLYNEUROPATHY PATIENTS WITH PACEMAKER IMPLANTATION
- PO 35 CLINICAL OUTCOMES IN FAMILIAL AMYLOID POLYNEUROPATHY PATIENTS: THE EFFECT OF PACEMAKER IMPLANTATION
- PO 36 MULTIPARAMETRIC ECHOCARDIOGRAPHY SCORES FOR TRANSTHYRETIN CARDIAC AMYLOIDOSIS DIAGNOSIS - IS THE INCREASED WALL THICKNESS SCORE APPROPRIATE?
- PO 37 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) CARDIOGENOMICS: A TERTIARY CENTRE EXPERIENCE
- PO 38 ATTR-CM UNDER THE MICROSCOPE: COMPARING REAL-WORLD WITH TRIAL OUTCOMES
- PO 39 NAVIGATING TAFAMIDIS OUTCOMES ACROSS DIFFERENT DISEASE SEVERITIES IN ATTR-CM
- PO 40 NON-CONVENTIONAL VERSUS CONVENTIONAL PACING IN CARDIAC AMYLOIDOSIS: IMPACT ON CLINICAL, ELECTRICAL, AND FUNCTIONAL OUTCOMES
- PO 41 RIGHT VENTRICULAR FUNCTION ANALYSIS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: IDENTIFYING THE BEST PREDICTOR OF PATIENT OUTCOMES
- PO 42 PREDICTORS OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: INSIGHTS FROM A REGIONAL HOSPITAL EXPERIENCE
- PO 43 ACUTE KIDNEY INJURY, THE WORST NIGHTMARE IN PATIENTS WITH MYOCARDIAL INFARCTION AND CARDIOGENIC SHOCK
- PO 44 CONTRAST VOLUME TO CREATININE CLEARANCE RATIO - A STRONG PREDICTOR OF CONTRAST INDUCED NEPHROPATHY IN PATIENTS UNDERGOING PERCUTANEOUS INTERVENTION
- PO 45 RETHINKING AKI RISK: BEYOND CONTRAST VOLUME IN ACUTE MYOCARDIAL INFARCTION
- PO 46 SHOCK INDEX-CREATININE CLEARANCE IN ACUTE CORONARY SYNDROME
- PO 47 THE HEART-KIDNEY CONNECTION: ACUTE KIDNEY INJURY IN CARDIOGENIC SHOCK
- PO 48 LIPOPROTEIN A AND CARDIOVASCULAR RISK IN ACUTE MYOCARDIAL INFARCTION: WHAT HAVE WE LEARNED IN 5 YEARS?

- PO 49 PREVALENCE OF HIGH LIPOPROTEIN (A) LEVELS IN PATIENTS WITH PREMATURE MYOCARDIAL INFARCTION: SYSTEMATIC REVIEW
- PO 50 LIPOPROTEIN(A) LEVELS IN ACUTE MYOCARDIAL INFARCTION PATIENTS AND THEIR ASSOCIATIONS WITH PRIOR EVENTS AND CORONARY ARTERY DISEASE SEVERITY: A REAL-WORLD COHORT STUDY
- PO 51 HIGH-SENSITIVITY C-REACTIVE PROTEIN AS A PREDICTOR OF CARDIOVASCULAR EVENTS IN YOUNG PATIENTS FOLLOWING MYOCARDIAL INFARCTION.
- PO 52 STRATIFICATION OF CHEST PAIN IN THE EMERGENCY DEPARTMENT: HOW EFFECTIVELY DO RISK SCORES PREDICT CORONARY ARTERY STENOSIS?
- PO 53 IDENTIFYING PREDICTORS OF MISCLASSIFICATION IN OCCLUSION MYOCARDIAL INFARCTION
- PO 54 LONG-TERM OUTCOMES AND RISK FACTORS IN YOUNG ADULTS WITH ACUTE CORONARY SYNDROME: A DECADE OF EXPERIENCE
- PO 55 PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER UNSTABLE ANGINA: IS IT POSSIBLE?
- PO 56 PREDICTORS OF SIGNIFICANT CORONARY ARTERY DISEASE IN A CONTEMPORARY COHORT OF UNSTABLE ANGINA PATIENTS
- PO 57 INSIGHTS INTO LEFT VENTRICULAR SYSTOLIC FUNCTION RECOVERY FOLLOWING ACUTE CORONARY SYNDROME
- PO 58 MECHANICAL COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION: CLINICAL CHARACTERISTICS AND MORTALITY TRENDS
- PO 59 PREDICTORS OF CORONARY ARTERY DISEASE IN ACUTE HEART FAILURE PATIENTS: DO THEY ALL BENEFIT FROM INVASIVE CORONARY ANGIOGRAPHY?
- PO 60 UNCOVERING PREDICTORS OF ADVERSE OUTCOMES IN HFREF AFTER ACUTE MYOCARDIAL INFARCTION
- PO 61 GLP1 AGONISTS: PRESCRIBER INERTIA OR ACCESSIBILITY ISSUE?
- PO 62 CARDIAC REHABILITATION IN OBESE PATIENTS: A POPULATION AT INCREASED RISK
- PO 63 DIFFERENCES IN OVERWEIGHT AND OBESITY PREVALENCE AMONG PRIMARY SCHOOL CHILDREN IN SÃO JOÃO DA MADEIRA, PORTUGAL
- PO 64 COMPARISON BETWEEN OFFICE BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE MONITORING IN PREDICTING CARDIOVASCULAR EVENTS
- PO 65 EXPLORING CORRELATION BETWEEN ADIPOSITY AND BLOOD PRESSURE AND THE IMPACT OF EXERCISE IN PRIMARY SCHOOL CHILDREN FROM SÃO JOÃO DA MADEIRA.
- PO 66 IMPACT OF SUBCLINICAL PRIMARY ALDOSTERONISM ON VALVULAR, CORONARY AND AORTIC CALCIFICATION: A POPULATION-BASED COHORT STUDY
- PO 67 PACEMAKER IN NONAGENARIAN AND CENTENARIAN PATIENTS: A FIVE-YEAR EXPERIENCE AT A TERTIARY CENTER
- PO 68 GENDER DIFFERENCES IN NONAGENARIANS UNDERGOING PACEMAKER IMPLANTATION
- PO 69 CLINICAL OUTCOMES IN NONAGENARIANS UNDERGOING EMERGENT CORONARY ANGIOGRAPHY: A RETROSPECTIVE ANALYSIS
- PO 70 EVALUATING THE PREDICTIVE VALUE OF FRAILTY SCORES ON MORTALITY IN PATIENTS WITH CARDIOGENIC SHOCK ACROSS THE AGE SPECTRUM.
- PO 71 ADVANCED THERAPEUTIC INTERVENTIONS IN ELDERLY HEART FAILURE: OUTCOMES OF CARDIAC RESYNCHRONIZATION THERAPY
- PO 72 SEGMENTAL KINETIC DISTURBANCES: A POOR PREDICTOR OF CORONARY ARTERY DISEASE IN VERY ELDERLY PATIENTS WITH HEART FAILURE
- PO 73 MANAGING CARDIOVASCULAR RISK IN CANCER PATIENTS: THE IMPACT OF CANCER THERAPIES ON NEW-ONSET HEART FAILURE
- PO 74 A NEW ERA IN CARDIO-ONCOLOGY: UPRISING HEART FAILURE THERAPIES FOR CARDIO-PERMISSIVE STRATEGIES IN CANCER THERAPY-RELATED CARDIAC DYSFUNCTION
- PO 75 THE DELICATE BALANCE OF PERMISSIVE CARDIOTOXICITY STRATEGY IN CANCER-RELATED CARDIAC DYSFUNCTION AT A TERTIARY CENTRE: A COMPARATIVE ANALYSIS
- PO 76 CANCER THERAPY SUSPENSION DUE TO CARDIOVASCULAR TOXICITY: RISK FACTORS AND OUTCOMES
- PO 77 ANTHRACYCLINE CHEMOTHERAPY: IMPACT ON CARDIAC BIOMARKERS AND FITNESS
- PO 78 CARDIOTOXICITY IN IBRUTINIB-TREATED PATIENTS: INCIDENCE, MANAGEMENT, AND IMPACT ON TREATMENT OUTCOMES
- PO 79 PERFORMANCE OF GUIDELINE-SUGGESTED RISK SCORES FOR INFECTIVE ENDOCARDITIS IN A REAL-WORLD COHORT

- PO 80 IMPACT OF DELAYS IN DIAGNOSIS AND THERAPY ON MORTALITY IN PATIENTS WITH INFECTIVE ENDOCARDITIS
- PO 81 INFECTIVE ENDOCARDITIS AND ACUTE HEART FAILURE: A COHORT ANALYSIS OF RISK FACTORS AND MORTALITY
- PO 82 INFECTIVE ENDOCARDITIS - PREDICTORS OF CEREBRAL AND PERIPHERAL EMBOLIZATION AND MORTALITY
- PO 83 SPECIFIC PATHOGENS AND PROGNOSTIC OUTCOMES IN INFECTIVE ENDOCARDITIS: A RETROSPECTIVE ANALYSIS
- PO 84 AORTIC PROSTHETIC VALVE ENDOCARDITIS: CLINICAL CHARACTERISTICS, MICROBIOLOGICAL PROFILE AND OUTCOMES COMPARISON BETWEEN TRANSCATHETER AND SURGICAL BIOPROSTHESIS
- PO 85 THE FAILING FONTAN: FROM THE SUCCESSFUL PALLIATION TO THE UNAVOIDABLE NOT-SO-SLOWLY PROGRESSIVE FAILURE OF THE CIRCUIT
- PO 86 ADULTS WITH FONTAN CIRCULATION: INSIGHTS FROM A PORTUGUESE ADULT CONGENITAL HEART DISEASE CENTER
- PO 87 SIX-MINUTE WALKING TEST AND CARDIOPULMONARY EXERCISE TEST IN PULMONARY HYPERTENSION RISK ASSESSMENT
- PO 88 OXYGEN THERAPY IN CTEPH PATIENTS: PREVALENCE AND ASSOCIATED FACTORS
- PO 89 PROGNOSTIC VALUE OF THE COMPOSITE PULMONARY EMBOLISM SHOCK SCORE IN ACUTE INTERMEDIATE-RISK PULMONARY EMBOLISM
- PO 90 INCIDENCE OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER SEVERE FORMS OF ACUTE PULMONARY EMBOLISM: SYSTEMATIC REVIEW WITH META-ANALYSIS
- PO 91 RIGHT ATRIAL PRESSURE ESTIMATION BY ECHOCARDIOGRAPHY IN PULMONARY HYPERTENSION - TIME FOR A CHANGE?
- PO 92 BREAKING NEW GROUND IN PULMONARY ENDARTERECTOMY: INITIAL EXPERIENCE OF A PORTUGUESE SINGLE CENTER
- PO 93 LONG-TERM SURVIVAL WITH PARENTERAL PROSTACYCLIN THERAPY IN PULMONARY HYPERTENSION - INSIGHTS FROM A REFERRAL CENTER IN PORTUGAL
- PO 94 QTC INTERVAL INDEPENDANTLY PREDICTS OUTCOMES IN ACUTE PULMONARY EMBOLISM
- PO 95 PULMONARY EMBOLISM IN ANTICOAGULATED PATIENTS: A RETROSPECTIVE SINGLE-CENTERED COHORT COMPARING DATA FROM THE PIOPED II STUDY
- PO 96 CLINICAL RULE FOR INFECTIVE ENDOCARDITIS IN THE EMERGENCY DEPARTMENT SCORE: A PREDICTION TOOL FOR INFECTIVE ENDOCARDITIS AND ITS EMBOLIC EVENTS
- PO 97 ANTIBIOTIC THERAPY FOR ENDOCARDITIS IN OUTPATIENT SETTING: IS IT INEFFECTIVE AND SAFE IN LOW RISK PATIENTS?
- PO 98 THE BURDEN OF INFECTIVE ENDOCARDITIS IN A CENTER WITHOUT CARDIAC SURGERY: A RETROSPECTIVE ANALYSIS
- PO 99 COMPREHENSIVE MANAGEMENT OF INFECTIVE ENDOCARDITIS: CLINICAL FINDINGS AND SURGICAL OUTCOMES
- PO 100 VANCOMYCIN THERAPY AND ACUTE KIDNEY INJURY IN PATIENTS WITH INFECTIVE ENDOCARDITIS
- PO 101 IS PROCALCITONIN A GOOD PREDICTOR FOR IN-HOSPITAL MORTALITY IN INFECTIVE ENDOCARDITIS?
- PO 102 ASSESSING THE ROLE OF AORTIC VALVE CALCIUM SCORE IN PATIENTS WITH SEVERE AORTIC STENOSIS AND CHRONIC KIDNEY DISEASE
- PO 103 SEX DIFFERENCES IN LEFT VENTRICULAR SYSTOLIC FUNCTION IN SEVERE AORTIC STENOSIS
- PO 104 THE MYOCARDIAL IMPACT OF RAPID PROGRESSION OF AORTIC STENOSIS
- PO 105 THE SODIUM FLUORIDE AORTIC GRADIENT: INSIGHTS FROM THE ROPPET-NAF STUDY
- PO 106 THE POTENTIAL ROLE OF ELEVATED LIPOPROTEIN(A) IN THE EARLY STAGES OF AORTIC VALVE STENOSIS
- PO 107 GENDER DIFFERENCE IMPACT ON TRANSCATHETER AORTIC VALVE REPLACEMENT OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSES
- PO 108 SEX-SPECIFIC DIFFERENCES IN ATRIAL REMODELLING AND RECURRENCE RISK AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION
- PO 109 MYOCARDIAL INFARCTION AND GENDER DIFFERENCES IN ELDERLY PATIENTS
- PO 110 BRIDGING THE GENDER GAP IN TAVI: REAL-WORLD EVIDENCE FROM A SINGLE-CENTER STUDY
- PO 111 SEX-DIFFERENCES AND LONG-TERM OUTCOMES AFTER AORTIC VALVE REPLACEMENT
- PO 112 UNDERINFORMED AND OVERLOOKED: THE STATE OF CARDIOVASCULAR HEALTH LITERACY IN PORTUGUESE WOMEN
- PO 113 ACUTE CORONARY SYNDROME IN YOUNG WOMEN: RISK FACTORS AND LONG-TERM PROGNOSIS
- PO 114 FROM GENES TO OUTCOMES: THE PROGNOSTIC ROLE OF GENETIC MUTATIONS IN DILATED CARDIOMYOPATHY
- PO 115 GENDER DIFFERENCES IN MYOCARDIAL REVERSE REMODELING AFTER GUIDELINE-DIRECTED MEDICAL THERAPY IN DILATED CARDIOMYOPATHY

- PO 116 PREDICTING ATRIAL FIBRILLATION - CAN ATRIAL PARAMETERS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE BE THE KEY IN DILATED CARDIOMYOPATHY?
- PO 117 FORECASTING VENTRICULAR ARRHYTHMIAS IN DILATED CARDIOMYOPATHY: A FOCUS ON CARDIAC IMPLANTABLE ELECTRONIC DEVICES PATIENTS
- PO 118 GENETIC MUTATIONS AND TESTING PROFILES LANDSCAPE IN DILATED CARDIOMYOPATHY PATIENTS: A DIAGNOSTIC IMPACT ANALYSIS
- PO 119 REFINING GENETIC PREDICTION IN DILATED CARDIOMYOPATHY: EVALUATING THE MADRID SCORE AND ENHANCED MACHINE LEARNING MODELS WITH CLINICAL AND IMAGING DATA
- PO 120 THE SPECTRUM OF HYPERTROPHIC CARDIOMYOPATHIES - WHERE IS FABRY?
- PO 121 ECHOCARDIOGRAPHIC DIFFERENTIATION OF CARDIAC AMYLOIDOSIS SUBTYPES
- PO 122 GENOTYPE-PHENOTYPE CORRELATIONS WITH LATE GADOLINIUM ENHANCEMENT PATTERNS IN PRIMARY CARDIOMYOPATHY
- PO 123 IMPACT OF NOVEL MAXIMAL WALL THICKNESS ADJUSTMENTS ON ARRHYTHMIC EVENT PREDICTION IN HYPERTROPHIC CARDIOMYOPATHY
- PO 124 MYOCARDIAL STRAIN CHANGES AS ASSESSED BY FEATURE TRACKING CMR IN PATIENTS WITH ACUTE MYOCARDITIS AND PRESERVED EJECTION FRACTION. IMPACT ON PROGNOSIS
- PO 125 CARDIAC MAGNETIC RESONANCE FINDINGS IN FABRY DISEASE
- PO 126 TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-ANALYSIS OF HOSPITALIZATION OUTCOMES IN HEART FAILURE AND SECONDARY MITRAL REGURGITATION
- PO 127 LEFT VENTRICULAR DYSFUNCTION AND TAVI - PREDICTORS OF RECOVERY AND OUTCOMES
- PO 128 PERCUTANEOUS MITRAL VALVE REPAIR VS SURGERY ON 12-MONTH MORTALITY/HOSPITALIZATIONS IN MITRAL REGURGITATION: A META-ANALYSIS OF CLINICAL TRIALS AND PROPENSITY-MATCHED COHORTS
- PO 129 A META-ANALYSIS OF QUALITY OF LIFE OUTCOMES AFTER TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION
- PO 130 RIGHT BUNDLE BRANCH BLOCK AND THE RISK OF PACEMAKER IMPLANTATION AFTER TAVI: AN OBSERVATIONAL STUDY
- PO 131 STRATEGIC TIMING IN TEER: SURVIVAL IMPLICATIONS FOR MITRAL REGURGITATION IN HEART FAILURE
- PO 132 THE ABCDE SCORE: A SIMPLE TOOL FOR PREDICTING 3-MONTH MORTALITY IN ACUTE HEART FAILURE PATIENTS
- PO 133 PORTUGUESE VERSION VALIDATION AND PREDICTIVE PERFORMANCE OF THE HEART FAILURE SYMPTOM TRACKER (HFAST) FOR 3- AND 6-MONTH HOSPITALIZATIONS
- PO 134 EJECTION FRACTION IN HEART FAILURE AND INTENSIVE CARE ADMISSION: WHAT IS THE PROGNOSTIC IMPACT?
- PO 135 A NOVEL RISK SCORE COMBINING BIOMARKERS OF HYPERVOLEMIA PREDICTS 1-YEAR OUTCOMES IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION
- PO 136 PERFORMANCE OF MORTALITY RISK SCORES IN ADVANCED HEART FAILURE PATIENTS: A RETROSPECTIVE COHORT STUDY
- PO 137 CLINICAL CHARACTERISTICS AND OUTCOMES OF DE NOVO VERSUS ACUTE DECOMPENSATED HEART FAILURE: ARE THEY SIMILAR?
- PO 138 HEART TRANSPLANT IN ACUTELY ILL PATIENTS: TIME ON WAITING LIST AND 1-YEAR MORTALITY
- PO 139 IMPACT OF THE HEARTMATE 3 ON QUALITY OF LIFE IN HEART FAILURE: A STUDY USING EQ-5D-5L
- PO 140 ASSESSMENT OF PALLIATIVE CARE NEEDS IN ADVANCED HEART FAILURE PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES
- PO 141 CAUSES AND PROGNOSTIC IMPLICATIONS OF HOSPITAL ADMISSIONS FOLLOWING SUCCESSFUL HEART TRANSPLANTATION
- PO 142 THE ROLE OF MULTIDISCIPLINARY HEART FAILURE OUTPATIENT CLINICS IN THE MANAGEMENT AND PROGNOSIS OF PATIENTS WITH ADVANCED HEART FAILURE
- PO 143 PREDICTORS OF CARDIAC ALLOGRAFT VASCULOPATHY AND DYSFUNCTION IN HEART TRANSPLANTATION: A SINGLE-CENTER STUDY
- PO 144 CLINICAL AND BIOCHEMICAL CHARACTERISTICS ASSOCIATED WITH IMPROVED HEART FAILURE OUTCOMES FOLLOWING A TELEMONITORING PROGRAM
- PO 145 TELECONSULTATION: A TOOL TO SUPPORT PEOPLE WITH HEART FAILURE
- PO 146 PREVENTION OF HEART FAILURE HOSPITALIZATION BASED ON REMOTE MONITORING AND EARLY INTERVENTION
- PO 147 THE HIDDEN COST OF ANTHRACYCLINES: CARDIAC DYSFUNCTION AND FUNCTIONAL IMPAIRMENT IN BREAST CANCER

- PO 148 ANÁLISE CUSTO-EFETIVIDADE DA ANGIOPLASTIA PULMONAR SOB TERAPÊUTICA VASODILATADORA PULMONAR VERSUS TERAPÊUTICA VASODILATADORA PULMONAR ISOLADA EM DOENTES COM HPTEC
- PO 149 ARTIFICIAL INTELLIGENCE-DRIVEN PHONOCARDIOGRAM ANALYSIS FOR NONINVASIVE DETECTION OF PULMONARY HYPERTENSION
- PO 150 PREDICTORS OF ACUTE KIDNEY INJURY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 151 ATRIOVENTRICULAR VALVE REGURGITATION PROGRESSION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 152 CONDUCTION ABNORMALITIES POST-TAVI: IMPACT ON LVEF RECOVERY AND SURVIVAL
- PO 153 KIDNEY FUNCTION FOLLOWING PERCUTANEOUS TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) IN HOSPITALIZED PATIENTS
- PO 154 EARLY AND LATE PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 155 PREDICTORS OF LEFT VENTRICULAR DYSFUNCTION RECOVERY ONE YEAR AFTER TAVR IN PATIENTS WITH PRE-EXISTING LEFT VENTRICULAR DYSFUNCTION (LVEF > 50%)
- PO 156 BRIDGING THE GENDER GAP IN CARDIAC REHABILITATION: LONGITUDINAL PATTERNS OF PHYSICAL ACTIVITY ENGAGEMENT
- PO 157 ASSESSMENT OF BALANCE AND PHYSICAL CONDITION AS MEASURES: EVALUATE EFFECTIVENESS OF A CARDIAC REHABILITATION PROGRAMME IN IMPROVING CARDIAC FUNCTION AND FUNCTIONAL CAPACITY.
- PO 158 CARDIAC REHABILITATION: IMPROVING FITNESS AND PERFORMANCE METRICS IN CORONARY ARTERY DISEASE
- PO 159 HIGH-INTENSITY INTERVAL AND CONTINUOUS TRAINING FOR HEART TRANSPLANT PATIENTS AND ITS IMPACT ON HEART RATE RECOVERY
- PO 160 RESTING ENERGY EXPENDITURE AS A SURROGATE OF MUSCLE MASS QUANTIFICATION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: A PILOT PROSPECTIVE COHORT STUDY
- PO 161 THE ROLE OF CPET FOR THE ASSESSMENT OF PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
- PO 162 ASSOCIATION OF SLC30A8 RS1326634 GENE VARIANT WITH CENTRAL FAT DISTRIBUTION IN OVERWEIGHT AND OBESE WOMEN
- PO 163 CAN THE GENE VARIANT ZC3HC1 RS11556924 C>T INCREASE ESSENTIAL HYPERTENSION RISK? INFLUENCE OF SMOKING IN THE RELATIONSHIP.
- PO 164 GENETIC CONTRIBUTION TO CAD IN PATIENTS WITH FEW TRADITIONAL RISK FACTORS BUT A SEDENTARY LIFESTYLE
- PO 165 HOW GENETIC VARIANTS AND EXCESS OF WEIGHT INFLUENCE RISK OF CORONARY ARTERY DISEASE
- PO 166 THE ADDITION OF A POLYGENIC RISK SCORE TO A CLINICAL RISK SCORE IN THE PREDICTION OF CARDIOVASCULAR DISEASE
- PO 167 PREDICTORS AND OUTCOMES OF AMYLOID CARDIOMYOPATHY CAUSED BY TRANSTHYRETIN V30 MUTATION
- PO 168 TRAINING ON A BUDGET: INDUSTRY SPONSORSHIPS IN CARDIOLOGY RESIDENCY
- PO 169 CARDIOLOGY IN DECLINE: UNVEILING THE DOWNWARD TREND IN RESIDENT PREFERENCES
- PO 170 THE FIRST YEAR OF GENERIC NOACS: IMPLICATIONS FOR PATIENTS AND THE HEALTHCARE SYSTEM
- PO 171 THE EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS COMPARED TO WARFARIN FOR LV THROMBUS RESOLUTION
- PO 172 ASSESSING THE BEST ANTICOAGULATION STRATEGY FOR LEFT VENTRICLE THROMBUS AFTER ANTERIOR MYOCARDIAL INFARCTION
- PO 173 LOW DOSE COLCHICINE FOR SECONDARY PREVENTION IN PATIENTS WITH PREVIOUS ATHEROSCLEROTIC EVENT: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS
- PO 174 UNVEILING THE IMPACT OF ANTHRACYCLINE CHEMOTHERAPY ON RESTING AND EXERCISE ECHOCARDIOGRAPHY
- PO 175 EVALUATION OF MYOCARDIAL WORK DURING EXERCISE ECHOCARDIOGRAPHY IN A HEALTHY POPULATION
- PO 176 THE ATHLETE'S HEART: INSIGHTS INTO ATRIAL AND VENTRICULAR PERFORMANCE
- PO 177 THE INFLUENCE OF RESTING, EXERCISE-INDUCED HYPERTENSION AND CARDIAC REMODELING ON MYOCARDIAL WORK INDICES
- PO 178 LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION DURING DOBUTAMINE STRESS TEST ECHOCARDIOGRAPHY - PREDICTORS AND PROGNOSTIC IMPACT
- PO 179 SYSTOLIC FUNCTION PREDICTORS IN PATIENTS WITH TAKOTSUBO SYNDROME
- PO 180 LEFT ATRIAL APPENDAGE OCCLUSION IN CKD: A SAFE OPTION FOR STROKE PREVENTION OR JUST A PIPE DREAM?

- PO 181** DEVELOPMENT OF ATRIAL FIBRILLATION AFTER CAVOTRICUSPID ISTHMUS-DEPENDENT ATRIAL FLUTTER ABLATION: ANALYSIS OF INCIDENCE AND RISK FACTORS IN A PORTUGUESE TERTIARY CARE CENTER.
- PO 182** ANTICOAGULATION AFTER CAVOTRICUSPID ISTHMUS-DEPENDENT ATRIAL FLUTTER ABLATION: ESSENTIAL OR OVERUSED?
- PO 183** SEMAGLUTIDE AND ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 184** UNMASKING THE HEART'S RESPONSE: ATRIAL FIBRILLATION IN IBRUTINIB-TREATED PATIENTS
- PO 185** IMPACT OF CANCER THERAPIES ON ATRIAL FIBRILLATION: INCIDENCE, RISK FACTORS, AND CLINICAL IMPLICATIONS
- PO 186** INTRARENAL VENOUS DOPPLER GUIDED DIURETIC MANAGEMENT ON HOSPITAL STAY
- PO 187** INTERMITTENT LEVOSIMENDAN IN ADVANCED PALLIATIVE HEART FAILURE IMPROVES QUALITY OF LIFE AND REDUCES HEART FAILURE DECOMPENSATIONS: A SINGLE CENTER-EXPERIENCE
- PO 188** IMPROVEMENT OF FUNCTIONAL STATUS AND ENHANCED SURVIVAL ESTIMATES AFTER 330 LEVOSIMENDAN ADMINISTRATIONS
- PO 189** A REAL WORLD EXPERIENCE OF 330 LEVOSIMENDAN ADMINISTRATIONS
- PO 190** OPTIMAL INITIAL FUROSEMIDE DOSING IN ACUTE HEART FAILURE: IMPACT ON HOSPITALIZATION AND 1-YEAR MORTALITY
- PO 191** INTERMITTENT LEVOSIMENDAN THERAPY IN ADVANCED HEART FAILURE PATIENTS AWAITING HEART TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
- PO 192** PREDICTORS OF MORTALITY IN A LEAD-RELATED TRICUSPID REGURGITATION POPULATION - IS THE RIGHT VENTRICLE THE KEY?
- PO 193** SECONDARY MITRAL REGURGITATION SUBTYPES: LINKING ETIOLOGY, LEFT ATRIAL MECHANICS, AND CLINICAL PHENOTYPES
- PO 194** DEVELOPMENT OF TRICUSPID REGURGITATION AFTER LEFT-SIDE HEART SURGERY
- PO 195** THE IMPACT OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR ON FUNCTIONAL OUTCOMES IN SECONDARY MITRAL REGURGITATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 196** IMPACT OF LEFT VENTRICULAR VOLUME AND EFFECTIVE REGURGITANT ORIFICE AREA ON MORTALITY EFFECTS OF TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR: A META-REGRESSION ANALYSIS
- PO 197** SAFETY AND EFFICACY OF TRANSCATHETER EDGE-TO-EDGE REPAIR IN ATRIAL FUNCTIONAL MITRAL REGURGITATION
- PO 198** THE SAFETY OF EARLY DISCHARGE FOR LOW-RISK STEMI PATIENTS IDENTIFIED BY ZWOLLE RISK SCORE
- PO 199** TRENDS IN PRIMARY ANGIOPLASTY OUTCOMES: MORTALITY, PROCEDURAL ADVANCEMENTS, AND LESION TYPE EVOLUTION OVER TIME
- PO 200** ACUTE HEART FAILURE FOLLOWING ST-ELEVATION MYOCARDIAL INFARCTION: PATIENT PROFILING
- PO 201** CLINICAL PROFILE AND PREDICTORS OF 30-DAY ALL-CAUSE MORTALITY OF STEMI PATIENTS RECEIVING FIBRINOLYTIC THERAPY IN AN ULTRA-PERIPHERAL REGION
- PO 202** EFFECT OF AIR TEMPERATURE ON ACUTE MYOCARDIAL INFARCTION INCIDENCE: A STUDY IN THE CENTRE-SOUTH REGION OF PORTUGAL
- PO 203** EVALUATING THE BENEFITS OF HIGH-DOSE STATIN LOADING IN STEMI MANAGEMENT: INSIGHTS FROM A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
- PO 204** UNCOATING NEW STRATEGIES: DRUG-COATED BALLOONS AS A PROMISING CHOICE
- PO 205** TEMPORAL TREND OF DRUG ELUTING BALLOON OVER THE LAST 10 YEARS
- PO 206** EXPERIENCE WITH DRUG-ELUTED BALLOONS: INSIGHTS FROM A TERTIARY CARE CENTRE
- PO 207** THE PORTUGUESE PERSPECTIVE ON THE MANAGEMENT OF MINOCA PATIENTS
- PO 208** TAKOTSUBO SYNDROME IN THE 21ST CENTURY: A PORTUGUESE PICTURE FROM A TERTIARY CENTER
- PO 209** CLINICAL FEATURES AND OUTCOMES OF TAKOTSUBO SYNDROME
- PO 210** HIGH-SENSITIVITY TROPONIN I PEAK IN MINOCA - A USEFUL TOOL IN THE RIGHT CLINICAL CONTEXT?
- PO 211** THE HIDDEN THREAT OF SEPTIC CARDIOMYOPATHY: UNMASKING ITS IMPACT ON ICU SURVIVAL
- PO 212** DIAGNOSTIC PERFORMANCE OF BIOMARKERS IN PREDICTING SEPTIC CARDIOMYOPATHY: A STUDY ON PROCALCITONIN, NT-PROBNP, AND TROPONIN T IN SEPSIS PATIENTS
- PO 213** UNVEILING THE POPULATION DYNAMICS OF SEPSIS CARDIOMYOPATHY: A COMPREHENSIVE EVALUATION
- PO 214** MANAGEMENT OF NEW-ONSET ATRIAL FIBRILLATION IN THE INTENSIVE CARE UNIT: WHERE DO WE STAND?

- PO 215 ENDOMYOCARDIAL BIOPSY IN CARDIOGENIC SHOCK: EXPERIENCE FROM A CONTEMPORARY CICU PORTUGUESE COHORT
- PO 216 TAVI OUTCOME ANALYSIS IN OFF-LABEL ANATOMIC SETTINGS
- PO 217 TAVI IN PURE AORTIC INSUFFICIENCY: OUR CASE SERIES
- PO 218 TRANSCATHETER AORTIC VALVE REPLACEMENT IN DIALYSIS PATIENTS: SURVIVAL AND COMPLICATION RATES - A SINGLE CENTER EXPERIENCE
- PO 219 OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN YOUNG LOW-RISK PATIENTS: A COMPREHENSIVE META-ANALYSIS OF EFFICACY AND SAFETY.
- PO 220 ADDRESSING SMALL ANNULUS IN TAVR: PROCEDURAL SUCCESS AND CLINICAL OUTCOMES
- PO 221 CHALLENGES AND OUTCOMES OF AORTIC VALVE INTERVENTION: INSIGHTS FROM A SINGLE-CENTER STUDY ON SEVERE HIGH-GRADIENT AORTIC STENOSIS
- PO 222 CLASSIC CLARITY, PARADOXICAL PUZZLE: PROGNOSTIC EVALUATION IN LOW FLOW LOW GRADIENT AORTIC STENOSIS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 223 LEFT VENTRICULAR EJECTION FRACTION IMPROVEMENT AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT - PREDICTORS AND PROGNOSIS
- PO 224 INTRA-HOSPITAL OUTCOMES FOR TAVR UNDER 75: CAN IT HOLD A CANDLE TO SAVR?
- PO 225 EFFICACY AND SAFETY OF IMPELLA VERSUS STANDARD OF CARE IN CARDIOGENIC SHOCK SECONDARY TO ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW
- PO 226 VASCULAR COMPLICATIONS IN INTRA-AORTIC BALLOON PUMP PATIENTS: INSIGHTS FROM A 20-YEAR SINGLE-CENTER EXPERIENCE
- PO 227 PREDICTORS OF MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION MANAGED WITH INTRA-AORTIC BALLOON ASSISTANCE: A 20-YEARS SINGLE-CENTER EXPERIENCE
- PO 228 OUTCOMES OF EXTRACORPOREAL MEMBRANE OXYGENATION VS. INTRA-AORTIC BALLOON PUMP IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A RETROSPECTIVE COMPARATIVE ANALYSIS
- PO 229 PREDICTORS OF MORTALITY IN VA-ECMO PATIENTS: A RETROSPECTIVE COHORT ANALYSIS USING LASSO REGRESSION
- PO 230 SCAI CLASSIFICATION AS A PREDICTOR OF MORTALITY IN CARDIOGENIC SHOCK: WHAT IS THE BEST TIME TO CLASSIFY PATIENTS?
- PO 231 CLASSIC VERSUS NORMOTENSIVE CARDIOGENIC SHOCK: A SINGLE CENTER COMPARISON ANALYSIS
- PO 232 A SINGLE CENTER ANALYSIS EXPLORING MECHANICAL CIRCULATORY SUPPORT IN CARDIOGENIC SHOCK
- PO 233 PREDICTORS OF MORTALITY IN CARDIOGENIC SHOCK: CLINICAL STAGING AND CARDIOVASCULAR SUPPORT
- PO 234 FIBRINOGEN IS A PREDICTOR OF CEREBROVASCULAR DISEASE RISK IN A PORTUGUESE POPULATION
- PO 235 THE IMPORTANCE OF FIBRINOGEN AS A CARDIOVASCULAR RISK FACTOR
- PO 236 THE ROLE OF THE TRIGLYCERIDE-GLUCOSE INDEX AS A PREDICTOR OF CORONARY ARTERY DISEASE SEVERITY IN YOUNG PATIENTS
- PO 237 COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT MODEL OF LIPOPROTEIN (A) TESTING IN PORTUGUESE PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN SECONDARY PREVENTION
- PO 238 LIPOPROTEIN(A) AND ACUTE CORONARY SYNDROME: ASSOCIATIONS WITH SEX, AGE AND TRADITIONAL CARDIOVASCULAR RISK FACTORS
- PO 239 THE HIGH HDL CONTROVERSY CONTINUES: THE PROGNOSIS FOR WOMEN WITH A HIGH HDL PROFILE IS SERIOUSLY UNFAVOURABLE
- PO 240 LDL ON TARGET - STRIKE EARLY AND STRIKE STRONG... JUST STRIKE!
- PO 241 ASSOCIATION BETWEEN LIPOPROTEIN(A) AND RENAL FUNCTION: INSIGHTS FROM A CROSS-SECTIONAL STUDY
- PO 242 LONG-TERM LIPID TARGET ACHIEVEMENT AFTER ACUTE MYOCARDIAL INFARCTION AND ISCHEMIC STROKE: A REAL-WORLD ANALYSIS
- PO 243 EFFICACY AND SAFETY OF TICAGRELOR VERSUS CLOPIDOGREL IN ACUTE MYOCARDIAL INFARCTION-ASSOCIATED CARDIOGENIC SHOCK: A PROPENSITY SCORE-MATCHED ANALYSIS
- PO 244 ANTI-THROMBOTIC THERAPY FOR AMI-CS ON MECHANICAL CIRCULATORY SUPPORT: DO WE NEED DAPT?
- PO 245 PREDICTORS OF HEMORRHAGIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK UNDERGOING DUAL ANTIPLATELET THERAPY
- PO 246 ANTI-THROMBOTIC AND GLUCOSE LOWERING THERAPY IN PATIENTS WITH DIABETES AND CORONARY ARTERY DISEASE UNDERGOING PCI. FINAL REPORT ON TWO-YEAR OUTCOMES OF THE ARTHEMIS STUDY

- PO 247 TRENDS IN P2Y12 INHIBITOR USE AFTER ACUTE CORONARY SYNDROMES IN PORTUGAL: A DECADE OF INSIGHTS FROM THE PROACS REGISTRY
- PO 248 TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH STEMI TREATED WITH FIBRINOLYSIS: A RETROSPECTIVE REAL-WORLD ANALYSIS
- PO 249 COMPARATIVE IN-HOSPITAL OUTCOMES OF P2Y12 INHIBITORS FOLLOWING ACUTE CORONARY SYNDROMES: EVIDENCE FROM THE PROACS REGISTRY
- PO 250 EARLY DOAC THERAPY AFTER INVASIVE ACUTE PULMONARY EMBOLISM THERAPY: FAST TRACK PE?
- PO 251 ACUTE CORONARY SYNDROMES WITHOUT THE USUAL SUSPECTS: PREVALENCE AND CLINICAL OUTCOMES OF PATIENTS WITHOUT STANDARD MODIFIABLE RISK FACTORS (SMURF-LESS)
- PO 252 MYOCARDIAL WORK BY SPECKLE-TRACKING ECHOCARDIOGRAPHY IN PACEMAKER CARRIERS ACCORDING TO PACING SITE
- PO 253 GLOBAL LONGITUDINAL STRAIN AND STRAIN RATE AS MARKERS OF SUBCLINICAL SYSTOLIC DYSFUNCTION IN PATIENTS WITH MODERATE AORTIC STENOSIS
- PO 254 IMPACT OF CARDIOVASCULAR RISK FACTORS IN MYOCARDIAL WORK
- PO 255 OPTIMIZED MEDICAL THERAPY ENHANCES LEFT ATRIAL STRAIN IN HFREF PATIENTS: A NOVEL PROGNOSTIC INDICATOR
- PO 256 LEFT ATRIUM STRAIN ANALYSIS IN WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A PREDICTIVE TOOL FOR ATRIAL FIBRILLATION
- PO 257 ASSESSMENT OF LEFT VENTRICULAR MYOCARDIAL WORK PERFORMANCE IN PATIENTS WITH ESSENTIAL HYPERTENSION
- PO 258 EXPLORING RV-ARTERIAL COUPLING: COMPARING CMR-DERIVED RV STRAIN AND ECHO-BASED MYOCARDIAL WORK INDICES IN PRE-CAPILLARY PULMONARY HYPERTENSION
- PO 259 RESERVOIR STRAIN OUTPERFORMS TRADITIONAL ECHOCARDIOGRAPHIC PARAMETERS IN PREDICTING MORTALITY IN SECONDARY MITRAL REGURGITATION
- PO 260 LEFT ATRIAL STRAIN AS A PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 261 MEASURING INTEGRATED BACKSCATTER IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 262 IS RELATIVE AORTIC VALVE LOAD DETERMINANT OF LEFT VENTRICULAR REMODELING IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR SURGICAL VALVE REPLACEMENT?
- PO 263 ACCURACY OF COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR THE EXCLUSION OF CORONARY ARTERY DISEASE BEFORE TRANSCATHETER AORTIC VALVE IMPLANTATION
- PO 264 TOTAL FIBROCALCIFIC BURDEN OF THE AORTIC VALVE IN PATIENTS WITH AORTIC STENOSIS - ASSESSMENT BY A NEW CT METHOD AND COMPARATIVE PERFORMANCE WITH CALCIUM SCORING
- PO 265 PROGNOSTIC VALUE OF CARDIAC COMPUTED TOMOGRAPHY PARAMETERS TO PREDICT PRE-INTERVENTION OUTCOMES IN PATIENTS WITH SEVERE AORTIC STENOSIS
- PO 266 AORTIC CALCIUM SCORE AND TAVR: INSIGHTS INTO PROCEDURAL COMPLICATIONS AND DEVICE SELECTION
- PO 267 ROLE OF PREOPERATIVE CAROTID DUPLEX ULTRASOUND IN PATIENTS WITH SEVERE AORTIC STENOSIS REFERRED FOR INTERVENTION
- PO 268 IMPACT OF DIASTOLIC DYSFUNCTION IN PATIENTS WITH MODERATE AORTIC STENOSIS
- PO 269 IS MYOCARDIAL ADAPTATION DISTINCT IN PATIENTS WITH BICUSPID VERSUS TRICUSPID SEVERE AORTIC STENOSIS UNDERGOING SURGICAL VALVE REPLACEMENT?
- PO 270 NAVIGATING THE CORONARY CROSSROADS: LEFT MAIN ARTERY BIFURCATING LESIONS, A SINGLE CENTRE PCI RESULTS
- PO 271 SAFETY AND OUTCOMES OF IFR VS. FFR IN CORONARY REVASCLARIZATION: A REAL-WORLD COHORT STUDY
- PO 272 CORONARY PHYSIOLOGY IN IN PATIENTS WITH ANGINA AND NON-OBSTRUCTIVE CORONARY ARTERY DISEASE - PRELIMINARY DATA FROM MULTICENTER REGISTRY.
- PO 273 IMPLICATIONS OF USING A RADIATION PROTECTION CABIN IN THE CARDIAC CATHETERIZATION LABORATORY
- PO 274 ONE-YEAR OUTCOMES OF ALCOHOLIC SEPTAL ABLATION IN A TERTIARY REFERENCE CENTER
- PO 275 EXPLORING FUNCTIONAL CORONARY DISEASE BEYOND OBSTRUCTIVE LESIONS
- PO 276 TRENDS IN PHYSIOLOGY AND CORRELATION BETWEEN IFR AND FFR IN CORONARY PHYSIOLOGICAL ASSESSMENT: A DECADE OF REAL-WORLD DATA
- PO 277 CHARACTERIZATION OF PATIENTS WITH LEFT MAIN CORONARY ARTERY DISEASE IN NON-ACUTE SETTINGS
- PO 278 PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN CORONARY ARTERY: ACUTE AND CHRONIC DISEASE
- PO 279 EFFICACY, EFFICIENCY AND SAFETY OF PULSED FIELD ABLATION IN PATIENTS WITH ATRIAL FIBRILLATION

- PO 280 RENAL DENERVATION AS AN ADJUNCT TO PULMONARY VEIN ISOLATION IN ATRIAL FIBRILLATION ABLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
- PO 281 COMPARISON OF STANDARD-POWER AND VERY HIGH-POWER SHORT-DURATION PULMONARY VEIN ABLATION
- PO 282 NON-PULMONARY VEIN TRIGGERS - MAXIMIZING SUCCESS IN ATRIAL FIBRILLATION REDO PROCEDURES
- PO 283 REDUCING RECURRENCE, ENHANCING SUCCESS: THE ROLE OF SUBSTRATE MODIFICATION IN ATRIAL FIBRILLATION REDO PROCEDURES
- PO 284 HIGH-POWER ABLATION GUIDED BY ABLATION INDEX IN ATRIAL FIBRILLATION: A RETROSPECTIVE STUDY
- PO 285 OUTCOMES AFTER IMPLANTATION OF SUBCUTANEOUS-IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (S-ICDS) FOR SECONDARY PREVENTION
- PO 286 IMPLANTATION OF EXTRAVASCULAR ICD: A SINGLE-CENTRE EXPERIENCE
- PO 287 SUBCUTANEOUS VERSUS TRANSVENOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY: INSIGHTS FROM REAL-WORD EVIDENCE
- PO 288 PRO-BNP VARIATION AS A RISK MARKER OF VENTRICULAR ARRHYTHMIAS IN CRT PATIENTS
- PO 289 IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR - DO WE HAVE ALTERNATIVE PREDICTORS TO ADMINISTERED SHOCKS?
- PO 290 CRT IN PATIENTS REQUIRING ANTIBRADYCARDIA PACING - ARE THEY GOOD RESPONDERS?
- PO 291 BREAKING BOUNDARIES: HEMOGLOBIN, HEMATOCRIT AND HEART FAILURE - THE SGLT2 INHIBITOR CONNECTION
- PO 292 ELEVATED FERRITIN AS A POTENTIAL RISK MARKER FOR DISEASE SEVERITY AND PROGNOSIS IN HEART FAILURE
- PO 293 ROLE OF ORAL IRON IN HFREF AND DECREASED TRANSFERRIN SATURATION: A SECONDARY ANALYSIS OF IRONOUT-HF.
- PO 294 PREDICTING EVENTS IN FERROPENIC ACUTE HEART FAILURE PATIENTS: THE B12 PARADOX
- PO 295 UNRAVELLING THE UGLY TRUTH ABOUT SLEEP APNEA AND ADVANCED HEART FAILURE: A PORTUGUESE REAL-WORLD SETTING
- PO 296 HYPERURICEMIA: A MARKER OF SEVERE CONGESTION AND DISEASE BURDEN IN HEART FAILURE
- PO 297 INSIGHTS ON CARBON DIOXIDE INSUFFLATION TECHNIQUE FOR EPICARDIAL ACCESS ABLATION OF REFRACTORY ARRHYTHMIAS: SAFETY AND CLINICAL OUTCOMES
- PO 298 SUDDEN CARDIAC DEATH HCM RISK SCORES IN APICAL HYPERTROPHIC CARDIOMYOPATHY: AN UNMET NEED IN CLINICAL PRACTICE
- PO 299 NONINVASIVE ELECTROCARDIOGRAPHIC MAPPING VS. CONVENTIONAL ECG ANALYSIS IN PREDICTING VENTRICULAR TACHYCARDIA ORIGIN
- PO 300 BASELINE INTERVALS ON ELECTROCARDIOGRAM AS A SCREENING TOOL FOR DIAGNOSING BRUGADA SYNDROME IN FAMILY MEMBERS
- PO 301 SINUS RHYTHM LATE ACTIVATION ZONES AS A TARGET FOR IMPROVING VENTRICULAR TACHYCARDIA ABLATION OUTCOMES
- PO 302 IS NON-SUSTAINED VENTRICULAR TACHYCARDIA A KEY PLAYER IN NON-ISCHEMIC CARDIOMYOPATHY?
- PO 303 FEASIBILITY, SAFETY AND MID-TERM PARAMETERS STABILIZATION OF LEFT BUNDLE BRANCH PACING: A SINGLE CENTER EXPERIENCE
- PO 304 IS THERE AN OPTIMAL TIMING FOR DEVICE REIMPLANTATION AFTER LEAD EXTRACTION DUE TO CIED INFECTION?
- PO 305 NON-INFECTED LEAD EXTRACTIONS: A BETTER LONG-TERM SOLUTION?
- PO 306 QRS INTERVAL AND VENTRICULAR DYSSYNCHRONY - ROLE IN LEAD-RELATED TRICUSPID REGURGITATION
- PO 307 ABSORBABLE ANTIBACTERIAL ENVELOPE ELIMINATES ADDITIONAL EXPECTED CARDIAC IMPLANTABLE ELECTRONIC DEVICE INFECTIONS IN HIGH-RISK PATIENTS
- PO 308 PACING-INDUCED CARDIOMYOPATHY IN PATIENTS WITH A HIGH PERCENTAGE OF VENTRICULAR PACING: A RETROSPECTIVE STUDY
- PO 309 PORTUGUESE HEART FAILURE OBSERVATIONAL STUDY - MADEIRA (PORTHOS-MADEIRA): CHARACTERISTICS INDIVIDUALS WITH NT-PROBNP ELEVATION
- PO 310 PORTUGUESE HEART FAILURE OBSERVATIONAL STUDY - MADEIRA (PORTHOS-MADEIRA) PHASE 1: BASELINE CHARACTERISTICS
- PO 311 LONG-TERM CARDIOVASCULAR RISK ASSESSMENT IN PORTUGUESE CHRONIC KIDNEY DISEASE POPULATION: INSIGHTS FROM THE PREVENTTM SCORE
- PO 312 THE BURDEN OF MYOCARDIAL INJURY: UNVEILING PREDICTORS OF MORTALITY FROM HOSPITAL TO LONG-TERM OUTCOMES

- PO 313 BASELINE CARDIOVASCULAR RISK AND PRIMARY PREVENTION IN STEMI PATIENTS: INSIGHTS FROM A TERTIARY CENTER
- PO 314 IMPACT OF MATERNAL-FETAL OUTCOMES AND BREASTFEEDING ON CARDIAC REVERSE REMODELING
- PO 315 IS LIPOPROTEIN(A) A PREDICTOR OF COMPUTED TOMOGRAPHY ANGIOGRAPHY FINDINGS? A RETROSPECTIVE STUDY IN A TERTIARY CENTER
- PO 316 IMPACT OF CORONARY CALCIFICATION ON LIPID-LOWERING THERAPY DECISIONS FOLLOWING CORONARY COMPUTED TOMOGRAPHY WITH NON-OBSTRUCTIVE CORONARY DISEASE OR NON-DIAGNOSTIC RESULT
- PO 317 ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE - THE NEXT STEP IN PREDICT ATRIAL FIBRILLATION?
- PO 318 INCREMENTAL VALUE OF CARDIAC MRI OVER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF AORTIC REGURGITATION
- PO 319 FIBROSIS ASSESSMENT IN PATIENTS WITH FREQUENT VENTRICULAR EXTRASYSTOLES AND NORMAL ECHOCARDIOGRAMS: INSIGHTS FROM CARDIAC MRI
- PO 320 ATRIAL PARAMETERS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE AND ITS ASSOCIATION WITH ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 321 LONG-TERM COMPARATIVE EFFECTIVENESS OF A HEMODYNAMIC SENSOR-BASED CRT VERSUS STANDARD CRT: INSIGHTS INTO CARDIAC AND FUNCTIONAL IMPROVEMENTS
- PO 322 ARE PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY LESS DESERVING OF PRIMARY PREVENTION DEVICE IMPLANTATION?
- PO 323 RISK STRATIFICATION IN NONISCHEMIC DILATED CARDIOMYOPATHY: THE ROLE OF T1/T2 MAPPING AND EXTRACELLULAR VOLUME
- PO 324 CARDIOPULMONARY EXERCISE TESTING TO ASSESS THE EFFECT OF CARDIAC RESYNCHRONISATION THERAPY
- PO 325 THE IMPACT OF ATRIAL FIBRILLATION IN CARDIAC RESYNCHRONISATION THERAPY'S RESPONSE
- PO 326 PREDICTORS FOR ADVERSE OUTCOMES IN ICD/CRT-D PATIENTS: INSIGHTS FROM A SINGLE-CENTER STUDY
- PO 327 IMPACT OF OPTIMIZED MEDICAL THERAPY ON ICD SHOCKS AND SURVIVAL IN HEART FAILURE PATIENTS
- PO 328 TRANSFORMING HEART FAILURE CARE: THE IMPACT OF CARDIAC REHABILITATION
- PO 329 CARDIAC RESYNCHRONIZATION THERAPY IN SEVERE HEART FAILURE PATIENTS: THE ROLE OF ARNIS IN THE MODERN THERAPEUTIC LANDSCAPE
- PO 330 EVALUATING RISK SCORES FOR CRT RESPONSE AND CLINICAL OUTCOMES: FINDING THE IDEAL TOOL
- PO 331 IMPACT OF LOW HEMOGLOBIN VALUES IN CRT RESPONSE
- PO 332 LONG-TERM EFFECT OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS ON ICD AND CRT-D THERAPY OUTCOMES IN PATIENTS WITH HFREF
- PO 333 EARLY AND LONG-TERM OUTCOMES AFTER AORTIC VALVE REPAIR: A SYSTEMATIC REVIEW AND META-ANALYSIS USING RECONSTRUCTED INDIVIDUAL PATIENT DATA
- PO 334 CLINICAL AND IMAGING SURVEILLANCE OF SURVIVORS OF ACUTE TYPE A AORTIC DISSECTION
- PO 335 ADVERSE EVENTS WHILE WAITING FOR VALVULAR INTERVENTION: IDENTIFYING MODIFIABLE RISK FACTORS
- PO 336 PROSTHETIC VALVE ROCKING MOTION: A LOOK OVER THE LAST TEN YEARS IN A TERTIARY CARE CENTER
- PO 337 A META-ANALYSIS ON 12-MONTH EFFICACY OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR VS SURGERY ON MITRAL REGURGITATION
- PO 338 URGENT SURGERY FOR INFECTIVE ENDOCARDITIS: ARE WE FALLING BEHIND THE CLOCK?
- PO 339 PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: IS IT A CONSEQUENCE OF THE TYPE OF PROSTHESIS USED?
- PO 340 BALLOON VS SELF-EXPANDABLE VALVES - AV CONDUCTION DISTURBANCE
- PO 341 OVER- OR UNDER-SIZING OF VALVE PROSTHESES IN TAVR AND THE IMPORTANCE OF A BROADER RANGE OF SIZING OPTIONS TO ENSURE OPTIMAL VALVE FIT.
- PO 342 PROPRANOLOL FOR HEART RATE CONTROL IN PRE-TAVI CARDIAC CT: A PROSPECTIVE STUDY ON EFFICACY AND SAFETY IN SEVERE AORTIC STENOSIS PATIENTS
- PO 343 POST-TAVI PACEMAKER REQUIREMENT PREDICTION - SIMPLE MATH?
- PO 344 PREDICTORS OF EARLY STROKE AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- PO 345 IMPACT OF RIGHT VENTRICULAR DYSFUNCTION IMPROVEMENT IN HEART FAILURE PATIENTS TREATED WITH CARDIAC RESYNCHRONIZATION THERAPY
- PO 346 CARDIAC RESYNCHRONIZATION THERAPY FOR NON-LBBB PATIENTS AND QRS MID-RANGE: WORTH IT?

- PO 347 LONG TERM CLINICAL OUTCOME AND ECHOCARDIOGRAPHIC RESPONSE OF PATIENTS SUBMITTED TO UPGRADE TO CARDIAC RESYNCHRONIZATION THERAPY
- PO 348 CARDIAC RESYNCHRONISATION THERAPY'S RESPONSE IN PATIENTS WITH NON-LBBB QRS COMPLEX MORPHOLOGY
- PO 349 ECHOCARDIOGRAPHIC PREDICTORS OF SUSTAINED VENTRICULAR TACHYARRHYTHMIAS IN PATIENTS WITH CRT-D FOR PRIMARY PREVENTION
- PO 350 EVALUATING SUPERRESPONSE IN CRT: A CLINICAL EDGE OR JUST A REMODELING EFFECT?
- PO 351 OUTCOMES OF ATYPICAL FLUTTER ABLATION GUIDED EXCLUSIVELY BY SYSTEMATIC ANALYSIS OF HIGH-RESOLUTION MAPS (NO ENTRAINMENT MANEUVERS)
- PO 352 WILL IT BE BACK? PREDICTING RECURRENCE AFTER LEFT ATRIAL FLUTTER ABLATION
- PO 353 LEFT ATRIAL APPENDAGE OCCLUSION: RESULTS OF A LARGE LONG-TERM COHORT
- PO 354 ADVANCEMENTS IN ATYPICAL ATRIAL FLUTTER ABLATION: IMPACT OF EVOLVING TECHNIQUES AND TECHNOLOGIES ON OUTCOMES
- PO 355 IMPACT OF DIASTOLIC DYSFUNCTION ON QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS UNDERGOING CATHETER ABLATION
- PO 356 REDEFINING SUCCESS IN ATRIAL FIBRILLATION - EFFICACY OF REDO ABLATION PROCEDURE AND IMPORTANCE OF LEFT ATRIAL VOLUME
- PO 357 A SIMPLIFIED PREDICTIVE SCORE FOR ATRIAL FIBRILLATION RECURRENCE AFTER ELECTRICAL CARDIOVERSION USING ELECTROCARDIOGRAPHIC PARAMETERS: THE RECAF-SCORE
- PO 358 AF RE-ABLATION: A COMPARATIVE ANALYSIS OF THE EFFICACY OF INITIAL PVI PROCEDURES
- PO 359 GENDER DIFFERENCES IN ATRIAL FIBRILLATION PATIENTS UNDERGOING CATHETER ABLATION
- PO 360 COMPARISON OF REAL-WORLD MITRAL TEER OUTCOMES WITH COAPT AND MITRA-FR: A SINGLE-CENTER ANALYSIS
- PO 361 TRANSCATHETER EDGE-TO-EDGE MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION: A META-ANALYSIS OF MORTALITY OUTCOMES
- PO 362 ISOLATED TRICUSPID VALVE SURGERY PATIENT PROFILE, RISK SCORE AND OUTCOME ASSOCIATION: SINGLE CENTER EXPERIENCE
- PO 363 PREDICTORS AND OUTCOMES OF PROSTHESIS-PATIENT MISMATCH AFTER TRIFECTA BIOPROSTHETIC AORTIC VALVE REPLACEMENT
- PO 364 UNROOFING SURGERY FOR ANOMALOUS AORTIC ORIGIN OF THE RIGHT CORONARY ARTERY: A SINGLE CENTRE EXPERIENCE
- PO 365 INFLUENCE OF GENDER ON LIFE EXPECTANCY AFTER CORONARY ARTERY BYPASS SURGERY
- PO 366 ADDRESSING COMPLICATIONS IN INFECTIVE ENDOCARDITIS: THE CRITICAL ROLE OF SURGICAL INTERVENTION POST-2023 GUIDELINES
- PO 367 IMPACT OF ETIOLOGY, AGE AND LEFT VENTRICULAR EJECTION FRACTION ON 12-MONTH MORTALITY EFFECTS OF TRANSCATHETER EDGE-TO-EDGE REPAIR VS. SURGERY: A META-REGRESSION ANALYSIS
- PO 368 COMPARING 30-DAY OUTCOMES OF TRANSCATHETER EDGE-TO-EDGE REPAIR VS SURGERY IN MITRAL VALVE REGURGITATION: A META-ANALYSIS OF CLINICAL TRIALS AND PROPENSITY-MATCHED COHORTS
- PO 369 CARDIONEUROABLATION IN PATIENTS WITH HYPERVAGOTONIA - AN EFFECTIVE SOLUTION?
- PO 370 SIMPLIFIED TOOL FOR PREDICTING PACEMAKER IMPLANTATION IN PATIENTS WITH BRADYCARDIC SYNCOPE UNDERGOING IMPLANTABLE LOOP RECORDER MONITORING: THE PREDICT-PPM SCORE
- PO 371 PREDICTORS OF PACEMAKER IMPLANTATION IN PATIENTS UNDERGOING IMPLANTABLE LOOP RECORDER MONITORING FOR SUSPECTED BRADYCARDIC SYNCOPE
- PO 372 ENHANCING QUALITY OF LIFE IN REFLEX SYNCOPE PATIENTS: EFFICACY OF A STRUCTURED EDUCATIONAL PROGRAMME
- PO 373 MITRAL VALVE PROLAPSE: ARRHYTHMIC RISK AND PROGNOSIS
- PO 374 DO IMPLANTABLE LOOP RECORDERS HAVE A ROLE IN HYPERTROPHIC CARDIOMYOPATHY?
- PO 375 THE EASY-WPW ALGORITHM IN PRACTICE: REAL-WORLD ACCURACY IN PREDICTING ACCESSORY PATHWAY LOCATIONS
- PO 376 GENERAL ANAESTHESIA COMPARED TO CONSCIOUS SEDATION FOR CATHETER ABLATION OF ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA IN ADOLESCENTS
- PO 377 PAEDIATRIC CATHETER ABLATION IN A TERTIARY CENTRE: CONTEMPORARY CHARACTERIZATION AND CLINICAL OUTCOMES

- PO 378 18F-FDG UPTAKE: A POTENTIAL BIOMARKER FOR THORACIC AORTIC INFLAMMATION IN HYPERTENSIVE BREAST CANCER PATIENTS
- PO 379 CARDIOVASCULAR TOXICITY PREDICTION IN BREAST CANCER PATIENTS: THE HFA/ICOS RISK TOOL IN REAL-WORLD PRACTICE
- PO 380 CARDIOVASCULAR TOXICITY RISK STRATIFICATION IN CANCER PATIENTS: AN UNMET NEED IN CARDIO-ONCOLOGY
- PO 381 CHEMOTHERAPY-INDUCED CARDIOVASCULAR RISK FACTORS IN BREAST CANCER PATIENTS: WHAT'S NEW?
- PO 382 CARDIOTOXICITY ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: MYTH OR REALITY?
- PO 383 IMPLICATIONS OF MYOCARDIAL BRIDGING ON HEART RHYTHM IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 384 INTEGRATING GENETIC VARIANTS INTO HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION: A QUANTITATIVE AND COMPARATIVE ANALYSIS
- PO 385 ALPHA-TROPOMYOSIN GENE VARIANTS IN HYPERTROPHIC CARDIOMYOPATHY: CLINICAL FEATURES AND DISEASE PROGRESSION
- PO 386 LEFT VENTRICULAR EJECTION FRACTION AS A PREDICTOR OF MAJOR VENTRICULAR ARRHYTHMIC EVENTS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS WITH AN ICD IN PRIMARY PREVENTION
- PO 387 SCREENING FOR ANDERSON-FABRY DISEASE IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY AND DISEASE-RELATED "RED FLAGS"
- PO 388 ATRIAL FIBRILLATION PREDICTORS GENERATED BY ARTIFICIAL INTELLIGENCE IN CARDIAC MAGNETIC RESONANCE IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
- PO 389 LEFT ATRIAL APPENDAGE OCCLUSION IN COMBINATION WITH ANOTHER CARDIAC PROCEDURE: A MORE EFFICIENT APPROACH?
- PO 390 SEX DIFFERENCES IN PATENT FORAMEN OVALE CLOSURE: IMPACT ON OUTCOMES AND COMPLICATIONS
- PO 391 OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN ANTICOAGULATION FAILURE VS CONTRAINDICATION
- PO 392 COMPARATIVE OUTCOMES OF IN SITU FIBRINOLYSIS VERSUS MECHANICAL AND COMBINED TECHNIQUES IN REDUCING RIGHT HEART PRESSURES AND MORTALITY IN PULMONARY EMBOLISM PATIENTS
- PO 393 IMPACT OF MECHANICAL THROMBECTOMY USING THE FLOWTRIEVER SYSTEM ON HEMODYNAMICS AND SAFETY IN ACUTE PULMONARY EMBOLISM
- PO 394 RISK ASSESSMENT IN PATIENTS WITH INTERMEDIATE TO HIGH-RISK PULMONARY EMBOLISM: CAN THE VALIDATED SCORES HELP PREDICT THE NECESSITY FOR REPERFUSION THERAPY?
- PO 395 ENCERRAMENTO DE FOP POR SÍNDROME DE PLATIPNEIA-ORTODEOXIA NUM CENTRO NACIONAL